Tranzyme, Inc. (NASDAQ: TZYM) is showing the dark side of the risks around biotech initial public offerings. After less than a year since its initial public offering, this stock just lost more than 40% of its market value after its experimental bowel drug candidate failed to improve post-surgery gastrointestinal recovery. This was the first of two late-stage trials and unfortunately it performed no better than the placebo in Phase III.
While a second trial is ongoing, Tranzyme does not plan any new drug application efforts as the company is shifting its focus into an oral program. More data from the second late-stage study is expected to be released late in the second quarter of this year.
The placebo-comparison was in both dose groups. The company’s other effort is focused on an oral drug TZP-102 in a phase II trial aimed at treating diabetic gastroparesis.
Shares were down well over 50% but there has been a bounce as investors still hold out some hope for the company. One thing that may hurt is that the value is now only $71 million after a 43% drop to $2.97. As of the end of 2011, Tranzyme still had $40.9 million in cash and cash equivalents and a total net tangible asset value of about $24.5 million.
Tranzyme may be down, but its prospects are not entirely out here as of today.
JON C. OGG
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.